|
Apr 8
|
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
|
|
Apr 6
|
Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers
|
|
Apr 4
|
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
|
|
Apr 4
|
ALS drug will be pulled from US market after study showed patients didn't benefit
|
|
Apr 4
|
UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets
|
|
Apr 4
|
Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market
|
|
Apr 4
|
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
|
|
Apr 4
|
Amylyx to pull ALS drug from market in rare move
|
|
Mar 27
|
European study finds popular ALS drug ineffective
|
|
Mar 14
|
3 Pharma Stocks to Sell in March Before They Crash & Burn
|
|
Mar 14
|
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
|
|
Mar 14
|
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
|
|
Mar 13
|
Analysts on Wall Street Lower Ratings for These 10 Stocks
|
|
Mar 12
|
After surprise trial failure, ALS doctors brace for one less treatment option
|
|
Mar 11
|
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
|
|
Mar 11
|
Amylyx CEOs look for a path forward following major setback
|
|
Mar 10
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Analysts Are Reducing Their Forecasts For This Year
|
|
Mar 10
|
Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.
|
|
Mar 8
|
Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure
|
|
Mar 8
|
Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work
|